{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:13:02Z","timestamp":1793862782546,"version":"4.6.1"},"reference-count":43,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      The treatment of major depressive disorder (MDD) with available antidepressant drugs is characterized by considerable ineffectiveness. Classical psychedelics such as psilocybin and N,N-dimethyltryptamine (DMT), which act primarily as 5-hydroxytryptamine 2A (5-HT\n                      <jats:sub>2A<\/jats:sub>\n                      ) receptor agonists, have shown preliminary efficacy for inducing long-term remission in MDD after one or two doses. GM-2505 is a novel, 5-HT\n                      <jats:sub>2A<\/jats:sub>\n                      receptor agonist, developed for treating MDD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this single-ascending dose, randomized, placebo-controlled, double-blind study, we characterized GM-2505\u2019s safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profile in 48 healthy participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Single intravenous (IV) doses up to 20\u2009mg demonstrated an acceptable safety profile of mild transient adverse events, short-term, non-clinically significant increases in blood pressure and pulse, and no significant changes in electrocardiographs, consistent with other 5-HT\n                      <jats:sub>2A<\/jats:sub>\n                      receptor agonists. In general, GM-2505\n                      <jats:italic toggle=\"yes\">C<\/jats:italic>\n                      <jats:sub>max<\/jats:sub>\n                      and AUC\n                      <jats:sub>last<\/jats:sub>\n                      increased dose proportionally, with\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      <jats:sub>1\/2<\/jats:sub>\n                      of 40\u201350\u2009minutes. Generally, dose-dependent effects were observed for neuroendocrine hormones, several neuropsychological and neurophysiological measures, and subjective drug effects. Dose-related effects were also observed in resting-state electroencephalography (rsEEG), with decreased power in the low frequency rsEEG bands (theta and alpha), and increased in the high frequency bands (slow and fast gamma).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      These PD findings were similar in nature and magnitude to other 5-HT\n                      <jats:sub>2A<\/jats:sub>\n                      receptor agonists that have been studied clinically. In line with the GM-2505 PK profile, the duration of cardiovascular and subjective effects was shorter than psilocybin but longer than DMT, demonstrating a potentially more practical temporal profile for use in a supervised clinical setting compared to longer-acting 5-HT\n                      <jats:sub>2A<\/jats:sub>\n                      receptor agonists, with an optimal dose range of 10\u201315\u2009mg IV. Clinical trial (ISRCTN64428072) registration: https:\/\/www.isrctn.com\/ISRCTN64428072.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811251378512","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:45:30Z","timestamp":1760618730000},"page":"166-178","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["A novel psychedelic 5-HT\n                    <sub>2A<\/sub>\n                    receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8103-4306","authenticated-orcid":false,"given":"Gerard J.","family":"Marek","sequence":"first","affiliation":[{"name":"Gilgamesh Pharmaceuticals Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soma","family":"Makai-B\u00f6l\u00f6ni","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, Leiden, The Netherlands"},{"name":"Leiden University Medical Center, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Umbricht","sequence":"additional","affiliation":[{"name":"Gilgamesh Pharmaceuticals Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P.","family":"Christian","sequence":"additional","affiliation":[{"name":"Gilgamesh Pharmaceuticals Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Winters","sequence":"additional","affiliation":[{"name":"Gilgamesh Pharmaceuticals Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dino","family":"Dvorak","sequence":"additional","affiliation":[{"name":"Gilgamesh Pharmaceuticals Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Raines","sequence":"additional","affiliation":[{"name":"Gilgamesh Pharmaceuticals Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7174-0944","authenticated-orcid":false,"given":"Zo\u00eb A.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Gilgamesh Pharmaceuticals Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric W.","family":"Austin","sequence":"additional","affiliation":[{"name":"Gilgamesh Pharmaceuticals Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1640-9324","authenticated-orcid":false,"given":"Adam K.","family":"Klein","sequence":"additional","affiliation":[{"name":"Gilgamesh Pharmaceuticals Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Leong","sequence":"additional","affiliation":[{"name":"Gilgamesh Pharmaceuticals Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fas J.","family":"Krol","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, Leiden, The Netherlands"},{"name":"Leiden University Medical Center, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne J. van der","family":"Graaf","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Juachon","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marije E.","family":"Otto","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, Leiden, The Netherlands"},{"name":"Leiden Academic Centre for Drug Research, Leiden University, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura G. J. M.","family":"Borghans","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, Leiden, The Netherlands"},{"name":"Leiden University Medical Center, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabri\u00ebl","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, Leiden, The Netherlands"},{"name":"Leiden University Medical Center, The Netherlands"},{"name":"Department of Psychiatry, Leiden University Medical Centre, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Kruegel","sequence":"additional","affiliation":[{"name":"Gilgamesh Pharmaceuticals Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Sporn","sequence":"additional","affiliation":[{"name":"Gilgamesh Pharmaceuticals Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115609019"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32802-7"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-011613-135918"},{"issue":"1","key":"e_1_3_2_5_1","first-page":"11","article-title":"Simple, automatic noncompartmental analysis: The PKNCA R package","volume":"42","author":"Denney W","year":"2015","unstructured":"Denney W, Duvvuri S, Buckeridge C (2015). Simple, automatic noncompartmental analysis: The PKNCA R package. Journal of Pharmacokinetics and Pharmacodynamics 42(1): 11\u2013107.","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-02148-w"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979351"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0193-953X(02)00107-7"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001547"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1176\/ps.2009.60.11.1439"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206443"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddtec.2016.07.004"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-003-1640-6"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.2546"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-022-01297-2"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2024.07.003"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.120.000056"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108093587"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2022_313"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00814"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4610-0"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2017.86"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.12.023"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2063-13.2013"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.011478"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674371506000104"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2016.01.005"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2011.228"},{"key":"e_1_3_2_29_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2023","unstructured":"R Core Team (2023) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing."},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.14530"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881120914206"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.22181"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.11.1905"},{"key":"e_1_3_2_34_1","unstructured":"SAS Institute Inc. (2014) MarketLine company profile. SAS Institute."},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2014.11.015"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4733-3"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1994.03950020009001"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012412"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.11.1217"},{"issue":"13","key":"e_1_3_2_40_1","article-title":"Human brain effects of DMT assessed via EEG-fMRI","volume":"120","author":"Timmermann C","year":"2023","unstructured":"Timmermann C, Roseman L, Haridas S, et al. (2023) Human brain effects of DMT assessed via EEG-fMRI. Proceedings of the National Academy of Sciences of the United States of America 120(13): e2218949120.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51974-4"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104793"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02477-4"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101809"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251378512","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811251378512","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251378512","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:01:20Z","timestamp":1782205280000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811251378512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1177\/02698811251378512"],"URL":"https:\/\/doi.org\/10.1177\/02698811251378512","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]}}}